ArticleScience translational medicine2021
Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR.
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Rapid diagnostic tests versus RT-PCR for Ebola virus infections: a systematic review and meta-analysis.Bulletin of the World Health Organization · 2022Pooled it
- Advances in detecting category A biothreat agents: Toward symptom-driven sensing strategies.Synthetic and systems biotechnology · 2026Review
- Article
- A Point-of-Care Test to Measure Tacrolimus Directly from Unprocessed Whole Blood.Analytical chemistry · 2026Article
- Crystal Structure of Měnglà Virus Nucleoprotein Bound by a Poorly Cross-Reactive Anti-Marburg Virus Nanobody Highlights a Single Amino Acid Affinity Switch, a Feature Also Evident in Dehong Virus.ACS infectious diseases · 2026Article
- Colorimetric Biosensors: Advancements in Nanomaterials and Cutting-Edge Detection Strategies.Biosensors · 2025Review
- Addressing Signal Drift and Screening for Detection of Biomarkers with Carbon Nanotube Transistors.ACS nano · 2024Article
- A Flexible, Quantitative Plasmonic-Fluor Lateral Flow Assay for the Rapid Detection ofACS infectious diseases · 2024Article
- Environmentally Resilient Microfluidic Point-of-Care Immunoassay Enables Rapid Diagnosis of Talaromycosis.ACS sensors · 2023Article
- Engineering Innovative Interfaces for Point-of-Care Diagnostics.Current opinion in colloid & interface science · 2023Review
- COVID-19 Diagnosis and SARS-CoV-2 Strain Identification by a Rapid, Multiplexed, Point-of-Care Antibody Microarray.Analytical chemistry · 2023Article
- Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report.Annals of the New York Academy of Sciences · 2022Article
- Rapid detection of an Ebola biomarker with optical microring resonators.Cell reports methods · 2022Article
- Technologies for Frugal and Sensitive Point-of-Care Immunoassays.Annual review of analytical chemistry (Palo Alto, Calif.) · 2022Review
- Synthetic nanobody-functionalized nanoparticles for accelerated development of rapid, accessible detection of viral antigens.Biosensors & bioelectronics · 2022Article
- Rapid test to assess the escape of SARS-CoV-2 variants of concern.Science advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
Abstract
Ebola virus (EBOV) hemorrhagic fever outbreaks have been challenging to deter due to the lack of health care infrastructure in disease-endemic countries and a corresponding inability to diagnose and contain the disease at an early stage. EBOV vaccines and therapies have improved disease outcomes, but the advent of an affordable, easily accessed, mass-produced rapid diagnostic test (RDT) that matches the performance of more resource-intensive polymerase chain reaction (PCR) assays would be invaluable in containing future outbreaks. Here, we developed and demonstrated the performance of a new ultrasensitive point-of-care immunoassay, the EBOV D4 assay, which targets the secreted glycoprotein of EBOV. The EBOV D4 assay is 1000-fold more sensitive than the U.S. Food and Drug Administration-approved RDTs and detected EBOV infection earlier than PCR in a standard nonhuman primate model. The EBOV D4 assay is suitable for low-resource settings and may facilitate earlier detection, containment, and treatment during outbreaks of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.